- Market Realist•15 days ago
On July 1, 2016, Alnylam Pharmaceuticals (ALNY) published positive preliminary results from its Phase 2 open label extension (or OLE) study.
Alnylam Pharmaceuticals, Inc.NasdaqGS
After hours: 68.290.00 (0.00%) as of 4:56 PM EDT
|Bid||63.60 x 600|
|Ask||70.00 x 200|
|52wk Range||49.96 - 130.00|
|Day's Range||66.61 - 69.00|
|Avg Vol (3m)||991,904|
As of 4:00 PM EDT. Market closed.